Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telavancin PK in Normal and Obese Subjects
NCT02753855Phase 1Completed
- Sponsor
- University of Illinois Chicago
- Start
- Apr 2016
- Primary completion
- Oct 2016
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of telavancin in bacterial infection, sponsored by University of Illinois Chicago. Primary endpoints: Number (%) of adverse events of any severity regardless of relationship to study drug at 48 hours, Area-under-the-plasma concentration-time curve (AUC0-infinity) at 48 hours and 1 more. Started Apr 2016; status: completed.
02
Drugs
telavancin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02753855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753855.